US Regulatory Reads, October 2017: Horror Stories, Super Offices And Artificial Intelligence
Executive Summary
Our "terrifying tales" of US FDA inspections that went awry attracted, by far, the most readers last month. Also popular in October: Medtech Insight's reporting on the US agency's move to bring its device evaluation, compliance and surveillance activities all under one roof, and our deep-dive look at the promise and challenges of applying artificial intelligence to quality operations.